S&P 500 7,674 -1.43% Nasdaq 26,180 -2.05% Dow Jones 53,277 -0.85% FTSE 100 10,817 +0.62% DAX 26,137 -1.15% Nikkei 225 65,969 -2.21% Hang Seng 25,508 +0.21% WTI Crude 85.64 +0.82% Gold 4,701 +7.67% US 10-Year Treasury Yield 4.738 +0.30% S&P 500 7,674 -1.43% Nasdaq 26,180 -2.05% Dow Jones 53,277 -0.85% FTSE 100 10,817 +0.62% DAX 26,137 -1.15% Nikkei 225 65,969 -2.21% Hang Seng 25,508 +0.21% WTI Crude 85.64 +0.82% Gold 4,701 +7.67% US 10-Year Treasury Yield 4.738 +0.30%

LATEST

U.S. to unveil 'greatest financial offensive' against Iran as Tehran threatens ship seizures●Stocks to buy in 2026 for long term: Jubilant FoodWorks, Max Financial among 5 stocks that could give 10-30% return●USF Athletics CEO Rob Higgins Has ‘Not A Second To Waste’ As Concrete Pours●Oil Prices Slide 2% as Markets Brace for Bessent’s ‘Economic D-Day’●Stocks to watch: Reliance Industries, Power Grid, IREDA among shares to be in focus today. Details here●BOJ Set to Offer Clues as Markets Bet Heavily on September Hike●Hedge Funds Ramp Up Dollar Shorts Ahead of Bessent’s Fiscal Plan●Taiwan Dollar’s August Rebound Is Looking Fragile, Analysts Say●U.S. to unveil 'greatest financial offensive' against Iran as Tehran threatens ship seizures●Stocks to buy in 2026 for long term: Jubilant FoodWorks, Max Financial among 5 stocks that could give 10-30% return●USF Athletics CEO Rob Higgins Has ‘Not A Second To Waste’ As Concrete Pours●Oil Prices Slide 2% as Markets Brace for Bessent’s ‘Economic D-Day’●Stocks to watch: Reliance Industries, Power Grid, IREDA among shares to be in focus today. Details here●BOJ Set to Offer Clues as Markets Bet Heavily on September Hike●Hedge Funds Ramp Up Dollar Shorts Ahead of Bessent’s Fiscal Plan●Taiwan Dollar’s August Rebound Is Looking Fragile, Analysts Say●

Asia

Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?

Markets-Economic Times · 2h ago · 🇮🇳 India

Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?

Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticosteroid and steroidal-hormone APIs. Its revenue primarily comes from international markets, with Europe being a significant contributor. Financials show steady revenue and EBITDA growth over recent years. Investors with a high-risk appetite may consider this long-term opportunity.

Read the full story at Markets-Economic Times →

More Asia

Stocks to buy in 2026 for long term: Jubilant FoodWorks, Max Financial among 5 stocks that could give 10-30% return

Markets-Economic Times · 34m ago

Stocks to watch: Reliance Industries, Power Grid, IREDA among shares to be in focus today. Details here

mint - markets · 41m ago

BOJ Set to Offer Clues as Markets Bet Heavily on September Hike

mint - markets · 42m ago

Taiwan Dollar’s August Rebound Is Looking Fragile, Analysts Say

mint - markets · 42m ago